Effect of ilozumab on PCSK9 and sICAM-1 levels in patients with angina pectoris of coronary heart disease

Objective:To explore the effect of ilozumab on the levels of proprotein convertase subtilisin/kexin type 9(PCSK9)and soluble intercellular adhesion molecule-1(sICAM-1)in patients with angina pectoris of coronary heart disease.Methods:A total of 106 patients with angina pectoris of coronary heart disease admitted to the Seventh Medical Center of Chinese PLA General Hospital from July 2021 to July 2022 were randomly divided into conventional treatment group and ilozumab group, with 53 cases in each group.The two groups were treated with diuretics, β-blockers and other conventional treatment, and the ilozumab group was treated with ilozumab on the basis of conventional treatment.The total effective rate, the occurrence of angina attacks, cardiac function, blood lipid, endothelial function, and the levels of PCSK9 and sICAM-1 were compared between the two groups.Results:The total effective rate of the ilozumab group was higher than that of the conventional treatment group(P< 0.05).The frequency and duration of angina attacks in the ilozumabgroup were lower than those in the conventional treatment group, left ventricular posterior wall thickness (LVPWd) level was lower than that in the conventional treatment group and the left ventricular ejection fraction(LVEF)level was higher than that in the conventional treatment group (P< 0.05).The levels of total cholesterol (TC), triglyceride (TG), endothelin-1(ET-1), troponin I (cTnI), hypersensitive troponin I(hs-TNI), PCSK9, sICAM-1 and low-density lipoprotein cholesterol (LDL-C) in the ilozumab group were lower than those in the conventional treatment group, while the level of nitric oxide(NO)was higher than that in the conventional treatment group(all P< 0.05).PCSK9 and sICAM-1 levels were positively correlated with LVPWd, TC, TG, ET-1, cTnI, hs-TNI and LDL-C, and negatively correlated with LVEF and NO (P< 0.05); PCSK9 was positively correlated with sICAM-1(P< 0.05).Conclusion:Ilozumab has a significant therapeutic effect on angina pectoris in patients with coronary heart disease.It can improve patients,cardiac function, lipid indexes and endothelial function, and reduce the levels of PCSK9 and sICAM-1.